
Viveve Medical VIVE
Quarterly report 2022-Q3
added 11-10-2022
Viveve Medical Total Assets 2011-2026 | VIVE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 25.9 M | 16.6 M | 27 M | 46.8 M | 36.1 M | 14.5 M | 11.5 M | 2.3 M | 1.56 M | 1.09 M | 3.55 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.8 M | 1.09 M | 17 M |
Quarterly Total Assets Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 12.2 M | 15.5 M | 20.7 M | 25.9 M | 30.4 M | 34 M | 37.7 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 27 M | 27 M | 27 M | 27 M | 46.8 M | 46.8 M | 46.8 M | 46.8 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 1.14 M | 1.14 M | 1.56 M | 1.56 M | 1.09 M | 1.09 M | 1.09 M | 1.09 M | 3.55 M | 3.55 M | 3.55 M | 3.55 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46.8 M | 1.09 M | 17.4 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Zimmer Biomet Holdings
ZBH
|
21.4 B | $ 88.57 | -0.65 % | $ 18 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Accuray Incorporated
ARAY
|
470 M | $ 0.4 | 4.21 % | $ 41.1 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Abbott Laboratories
ABT
|
86.7 B | $ 103.99 | -0.55 % | $ 181 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Align Technology
ALGN
|
6.21 B | $ 166.38 | -6.17 % | $ 12.5 B | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 10.93 | -5.12 % | $ 1.64 B | ||
|
AxoGen
AXGN
|
222 M | $ 31.28 | -3.01 % | $ 1.44 B | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 33.72 | -4.58 % | $ 5.02 K | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 69.17 | -1.43 % | $ 102 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 9.07 | -3.41 % | $ 257 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 34.58 | -5.62 % | $ 1.07 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Electromed
ELMD
|
53.8 M | $ 24.55 | 0.41 % | $ 208 M | ||
|
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.59 | -1.18 % | $ 32.1 M | ||
|
Aethlon Medical
AEMD
|
7.36 M | $ 2.15 | -5.29 % | $ 3.36 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 79.34 | -3.36 % | $ 46.4 B | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 11.2 | -1.84 % | $ 1.51 B | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 15.52 | -5.08 % | $ 364 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.92 | -4.48 % | $ 1.17 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Inogen
INGN
|
299 M | $ 6.19 | -4.77 % | $ 165 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 0.99 | -26.67 % | $ 16 M | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 85.33 | -1.73 % | $ 2.96 B | ||
|
Myomo
MYO
|
38.6 M | $ 0.7 | 2.32 % | $ 29.3 M | ||
|
Penumbra
PEN
|
1.83 B | $ 335.1 | -0.39 % | $ 13 B | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 61.85 | -2.83 % | $ 3.37 B | ||
|
LENSAR
LNSR
|
66.3 M | $ 6.07 | 9.96 % | $ 69.9 M | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 50.13 | -0.63 % | $ 1.47 B | ||
|
Medtronic PLC
MDT
|
91.7 B | $ 87.14 | 0.21 % | $ 112 B |